MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Edesa Biotech DSO Ratio 2011-2026 | EDSA
Annual DSO Ratio Edesa Biotech
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 97.1 | 193 | 71.1 | 2.06 | 24.6 | 75.8 | 55.5 | 119 | 21.6 | 20.4 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 193 | 2.06 | 68 |
Quarterly DSO Ratio Edesa Biotech
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 72.5 | 81.3 | 138 | 39.6 K | 39.6 K | 95 | - | - | - | 71.1 | 27.3 | 0.52 | 5.72 | 31.7 | 31.8 | 7.87 | 43.2 | 39.1 | 18.1 | 25.8 | 91.2 | 18.1 | 17.2 | 16.4 | 55.5 | 9.47 | 138 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 39.6 K | 0.52 | 3.21 K |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amarin Corporation plc
AMRN
|
157 | $ 14.81 | -0.34 % | $ 6.04 B |  Irlanda |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M |  USA |
 |
Legend Biotech Corporation
LEGN
|
3.53 K | $ 17.8 | -1.44 % | $ 18.7 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
53.8 | $ 3.24 | 13.85 % | $ 182 M | China |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.79 | -7.27 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.48 | -0.98 % | $ 8.37 B |  Australia |
 |
Biogen
BIIB
|
50.7 | $ 195.63 | 0.06 % | $ 28.7 B | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 216.28 | -0.83 % | $ 5 B |  Danmark |
 |
Bristol-Myers Squibb Company
BMY
|
83.9 | $ 60.51 | 1.12 % | $ 123 B | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Amneal Pharmaceuticals
AMRX
|
55.7 | $ 14.8 | 1.13 % | $ 4.57 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |